Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Whitehawk Therapeutics (WHWK) Other Non-Current Assets: 2018-2024

Historic Other Non-Current Assets for Whitehawk Therapeutics (WHWK) over the last 7 years, with Dec 2024 value amounting to $1.4 million.

  • Whitehawk Therapeutics' Other Non-Current Assets rose 30.50% to $2.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.0 million, marking a year-over-year increase of 30.50%. This contributed to the annual value of $1.4 million for FY2024, which is 25.03% down from last year.
  • Whitehawk Therapeutics' Other Non-Current Assets amounted to $1.4 million in FY2024, which was down 25.03% from $1.9 million recorded in FY2023.
  • In the past 5 years, Whitehawk Therapeutics' Other Non-Current Assets registered a high of $2.2 million during FY2021, and its lowest value of $20,000 during FY2020.
  • Its 3-year average for Other Non-Current Assets is $1.8 million, with a median of $1.9 million in 2023.
  • Its Other Non-Current Assets has fluctuated over the past 5 years, first plummeted by 50.00% in 2020, then skyrocketed by 10,965.00% in 2021.
  • Yearly analysis of 5 years shows Whitehawk Therapeutics' Other Non-Current Assets stood at $20,000 in 2020, then skyrocketed by 10,965.00% to $2.2 million in 2021, then dropped by 1.58% to $2.2 million in 2022, then declined by 14.33% to $1.9 million in 2023, then declined by 25.03% to $1.4 million in 2024.